Nurix Therapeutics share price today

(NRIX)

Nurix Therapeutics share price is $19.57 & ₹1,667.32 as on 25 Dec 2024, 2.30 'hrs' IST

$19.57

▲

-0.41

(-2.05%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Nurix Therapeutics share price in Dollar and Rupees. Guide to invest in Nurix Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Nurix Therapeutics. Get details on the Indian mutual funds that are investing in Nurix Therapeutics. Get Analyst recommendations and forecasts along with all the Nurix Therapeutics's financials.

Nurix Therapeutics share price movements

Today's Low: $19.14
Today's High: $19.70
$19.57
2.2%
Downside
Day's Volatility :2.84%
Upside
0.66%
52 Weeks Low: $7.65
52 Weeks High: $29.56
$19.57
60.91%
Downside
52 Weeks Volatility :74.12%
Upside
33.8%

Nurix Therapeutics Returns

Period	Nurix Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-15.68%	-9.0%	0.0%
6 Months	-5.64%	-4.6%	0.0%
1 Year	100.72%	3.0%	0.0%
3 Years	-35.52%	0.0%	-21.1%

Nurix Therapeutics Key Statistics

in dollars & INR

Previous Close	$19.98
Open	$19.77
Today's High	$19.7
Today's Low	$19.14
Market Capitalization	$1.4B
Today's Volume	$350.5K
52 Week High	$29.56
52 Week Low	$7.65
Revenue TTM	$56.4M
EBITDA	$-186.4M
Earnings Per Share (EPS)	$-2.9
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-57.96%

How to invest in Nurix Therapeutics from India?

It is very easy for Indian residents to invest directly in Nurix Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Nurix Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Nurix Therapeutics or NRIX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Nurix Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Nurix Therapeutics shares which would translate to 0.044 fractional shares of Nurix Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Nurix Therapeutics, in just a few clicks!

Returns in Nurix Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Nurix Therapeutics investment value today

Current value as on today

₹2,02,957

Returns

₹1,02,957

(+102.96%)

Returns from Nurix Therapeutics Stock

₹1,00,718 (+100.72%)

Dollar Returns

₹2,239 (+2.24%)

Indian investors sentiment towards Nurix Therapeutics

-38%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Search volume for Nurix Therapeutics on INDmoney from India has reduced in the last 30 days as on Dec 26, 2024. -38% less investors are searching Nurix Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Nurix Therapeutics

BlackRock Inc
9.63%
Redmile Group, LLC
6.04%
Vanguard Group Inc
5.66%
Baker Bros Advisors LP
5.48%
Deep Track Capital, LP
5.46%
Wellington Management Company LLP
4.92%

Analyst Recommendation on Nurix Therapeutics

Buy

88%Buy

11%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for Nurix Therapeutics(by analysts ranked 0 to 5 stars)

Based on 17 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Nurix Therapeutics

What analysts predicted

Upside of 63.22%

Current:

$19.57

Target:

$31.94

Insights on Nurix Therapeutics

Price Movement
In the last 1 year, NRIX stock has moved up by 102.2%
Increasing Revenue
Revenue is up for the last 2 quarters, 12.09M → 12.58M (in $), with an average increase of 3.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -41.51M → -48.95M (in $), with an average decrease of 8.6% per quarter
NRIX vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 25.2% return, outperforming this stock by 61.1%

Nurix Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$37.4M	-
Net Income	$-9.4M	-
Net Profit Margin	-25.18%	-

	FY19	Y/Y Change
Revenue	$31.1M	↓ 16.91%
Net Income	$-21.7M	↑ 130.15%
Net Profit Margin	-69.74%	↓ 44.56%

	FY20	Y/Y Change
Revenue	$17.8M	↓ 42.73%
Net Income	$-43.2M	↑ 99.28%
Net Profit Margin	-242.66%	↓ 172.92%

	FY21	Y/Y Change
Revenue	$29.8M	↑ 66.95%
Net Income	$-117.2M	↑ 171.02%
Net Profit Margin	-393.93%	↓ 151.27%

	FY22	Y/Y Change
Revenue	$38.6M	↑ 29.84%
Net Income	$-166.0M	↑ 41.68%
Net Profit Margin	-429.87%	↓ 35.94%

	FY23	Y/Y Change
Revenue	$77.0M	↑ 99.31%
Net Income	$-143.9M	↓ 13.31%
Net Profit Margin	-186.98%	↑ 242.89%

	Q2 FY23	Q/Q Change
Revenue	$30.7M	↑ 141.83%
Net Income	$-21.8M	↓ 38.33%
Net Profit Margin	-71.03%	↑ 207.52%

	Q3 FY23	Q/Q Change
Revenue	$18.5M	↓ 39.8%
Net Income	$-37.0M	↑ 69.73%
Net Profit Margin	-200.26%	↓ 129.23%

	Q4 FY23	Q/Q Change
Revenue	$15.2M	↓ 17.91%
Net Income	$-42.0M	↑ 13.45%
Net Profit Margin	-276.77%	↓ 76.51%

	Q1 FY24	Q/Q Change
Revenue	$16.6M	↑ 9.41%
Net Income	$-41.5M	↓ 1.04%
Net Profit Margin	-250.33%	↑ 26.44%

	Q2 FY24	Q/Q Change
Revenue	$12.1M	↓ 27.09%
Net Income	$-44.5M	↑ 7.29%
Net Profit Margin	-368.39%	↓ 118.06%

	Q3 FY24	Q/Q Change
Revenue	$12.6M	↑ 4.1%
Net Income	$-49.0M	↑ 9.9%
Net Profit Margin	-388.91%	↓ 20.52%

	FY18	Y/Y Change
Profit	$37.4M	-

	FY19	Y/Y Change
Profit	$-13.9M	↓ 137.14%

	FY20	Y/Y Change
Profit	$17.8M	↓ 228.11%

	FY21	Y/Y Change
Profit	$29.8M	↑ 66.95%

	FY22	Y/Y Change
Profit	$38.6M	↑ 29.84%

	FY23	Y/Y Change
Profit	$-112.2M	↓ 390.37%

	Q2 FY23	Q/Q Change
Profit	$27.3M	↑ 187.67%

	Q3 FY23	Q/Q Change
Profit	$15.1M	↓ 44.84%

	Q4 FY23	Q/Q Change
Profit	$11.4M	↓ 24.4%

	Q1 FY24	Q/Q Change
Profit	$12.7M	↑ 11.36%

	Q2 FY24	Q/Q Change
Profit	$8.0M	↓ 36.99%

	Q3 FY24	Q/Q Change
Profit	$8.4M	↑ 5.51%

	FY18	Y/Y Change
Operating Cash Flow	$-31.7M	-
Investing Cash Flow	$40.0M	-
Financing Cash Flow	$529.0K	-

	FY19	Y/Y Change
Operating Cash Flow	$601.0K	↓ 101.9%
Investing Cash Flow	$8.5M	↓ 78.75%
Financing Cash Flow	$126.0K	↓ 76.18%

	FY20	Y/Y Change
Operating Cash Flow	$-80.0K	↓ 113.31%
Investing Cash Flow	$-254.4M	↓ 3093.69%
Financing Cash Flow	$339.0M	↑ 268966.67%

	FY21	Y/Y Change
Operating Cash Flow	$-84.4M	↑ 105356.25%
Investing Cash Flow	$-108.3M	↓ 57.45%
Financing Cash Flow	$153.9M	↓ 54.61%

	FY22	Y/Y Change
Operating Cash Flow	$-159.8M	↑ 89.42%
Investing Cash Flow	$27.2M	↓ 125.12%
Financing Cash Flow	$117.2M	↓ 23.84%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-18.5M	↓ 61.88%
Investing Cash Flow	$43.8M	↑ 0.0%
Financing Cash Flow	$25.0K	↓ 98.31%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-41.1M	↑ 122.71%
Investing Cash Flow	$22.8M	↓ 48.04%
Financing Cash Flow	$1.7M	↑ 6716.0%

Nurix Therapeutics Technicals Summary

Sell

Neutral

Buy

Nurix Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Nurix Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Nurix Therapeutics Inc	-10.19%	-5.64%	100.72%	-35.52%	2.95%
Regeneron Pharmaceuticals, Inc.	-5.12%	-32.01%	-18.29%	12.56%	91.19%
Biontech Se	-3.72%	41.99%	6.11%	-55.22%	226.93%
Alnylam Pharmaceuticals, Inc.	-3.99%	-1.52%	23.75%	50.98%	112.09%
Vertex Pharmaceuticals Incorporated	-12.61%	-13.61%	0.03%	83.58%	86.41%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Nurix Therapeutics Inc	NA	NA	NA	-2.77	-0.58	-0.29	NA	5.62
Regeneron Pharmaceuticals, Inc.	17.67	17.67	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Nurix Therapeutics Inc	Buy	$1.4B	2.95%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$78.5B	91.19%	17.67	33.61%
Biontech Se	Buy	$27.4B	226.93%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$31.4B	112.09%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$105.1B	86.41%	32.84	-4.51%

About Nurix Therapeutics

nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. nurix is a leader in discovering a new class of drugs that work by modulating e3 ubiquitin ligases within the ubiquitin proteasome system (ups). the ups is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – offering therapeutic opportunities in multiple disease areas. nurix’s scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the ups, enabling the development of novel therapeutics that can restore normal cellular homeostasis. nurix was founded by internationally recognized experts in the ups field and received its initial funding from leading life science investors, third rock ventures and the column group. in 2015, nurix entered into a multi-year strategic collaboration with celgene to discover and develop next-generation therapies targe

Organization	Nurix Therapeutics
Employees	284
CEO	Dr. Arthur T. Sands M.D., Ph.D.
Industry	Health Technology

Management People of Nurix Therapeutics

Name	Title
Dr. Arthur T. Sands M.D., Ph.D.	CEO, President & Director
Mr. Johannes Van Houte	Chief Financial Officer
Dr. Gwenn M. Hansen Ph.D.	Chief Scientific Officer
Dr. John Kuriyan Ph.D.	Founder & Member of Scientific Advisory Board
Mr. Michael Rapé Ph.D.	Founder & Member of Scientific Advisory Board
Dr. Arthur Weiss M.D., Ph.D.	Founder & Member of Scientific Advisory Board
Rita Kwong	Senior Accounting Manager
Dr. Pasit Phiasivongsa Ph.D.	Chief Technical Officer
Dr. Christine Ring J.D., Ph.D.	Chief Legal Officer, Secretary & Chief Compliance Officer
Mr. Eric C. Schlezinger J.D.	Chief People Officer

Important FAQs about investing in Nurix Therapeutics from India :

What is Nurix Therapeutics share price today?

Nurix Therapeutics share price today stands at $19.57, Open: $19.77 ; Previous Close: $19.98 ; High: $19.70 ; Low: $19.14 ; 52 Week High: $29.56 ; 52 Week Low: $7.65. The stock opens at $19.77, after a previous close of $19.98. The stock reached a daily high of $19.70 and a low of $19.14, with a 52-week high of $29.56 and a 52-week low of $7.65.

Can Indians buy Nurix Therapeutics shares?

Yes, Indians can invest in the Nurix Therapeutics (NRIX) from India.

With INDmoney, you can buy Nurix Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Nurix Therapeutics at zero transaction cost.

How can I buy Nurix Therapeutics shares from India?

It is very easy to buy Nurix Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Nurix Therapeutics be purchased?

Yes, you can buy fractional shares of Nurix Therapeutics with INDmoney app.

What are the documents required to start investing in Nurix Therapeutics stocks?

To start investing in Nurix Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.